Biosyent Stock Based Compensation To Revenue from 2010 to 2024
| RX Stock | CAD 11.55 0.10 0.86% |
Stock Based Compensation To Revenue | First Reported 2010-12-31 | Previous Quarter 0.01625455 | Current Value 0.0103 | Quarterly Volatility 0.00449161 |
Check Biosyent financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Biosyent's main balance sheet or income statement drivers, such as Depreciation And Amortization of 478.1 K, Total Revenue of 33.2 M or Gross Profit of 26.4 M, as well as many indicators such as Price To Sales Ratio of 2.93, Dividend Yield of 0.0094 or PTB Ratio of 3.7. Biosyent financial statements analysis is a perfect complement when working with Biosyent Valuation or Volatility modules.
Biosyent | Stock Based Compensation To Revenue |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Biosyent Stock Analysis
When running Biosyent's price analysis, check to measure Biosyent's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Biosyent is operating at the current time. Most of Biosyent's value examination focuses on studying past and present price action to predict the probability of Biosyent's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Biosyent's price. Additionally, you may evaluate how the addition of Biosyent to your portfolios can decrease your overall portfolio volatility.